Lecigon
Advanced Parkinson's Disease
Phase 3Active
Key Facts
About Lobsor Pharmaceuticals
Lobsor Pharmaceuticals is a clinical-stage biotech company developing Lecigon, a continuous intestinal gel infusion of levodopa/carbidopa/entacapone for advanced Parkinson's disease. The technology aims to provide stable drug delivery, bypass erratic gastric emptying, and allow for a lower levodopa dose, potentially improving quality of life. Founded by executives with experience from the Duodopa product, the company is a privately held subsidiary of STADA Sweden, positioning it for strategic development and potential commercialization in the neurology space.
View full company profileTherapeutic Areas
Other Advanced Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lecigon® (U.S. name not specified) | Intrance Medical Systems | Phase 3 |
| Infudopa IntraV | Dizlin Pharmaceuticals | Pre-clinical |
| SER-252 (POZ-apomorphine) | Serina Therapeutics | Phase 1b |